Categories Earnings, Health Care

Johnson & Johnson Q1 earnings slide on flat revenue growth

Healthcare giant Johnson & Johnson (JNJ) kicked off pharma earnings as it posted its first-quarter 2019 earnings on Tuesday, April 16, before the opening bell.

Reported revenue for the quarter barely changed — inching just 0.1% higher — at $20 billion, while net earnings slipped 14% to $3.7 billion.

On a diluted basis, earnings fell 13% to $1.39 per share.

Johnson and Johnson JNJ Q1 2019 Earnings Infographic

On a non-GAAP basis, operational sales improved 4% year-over-year, while adjusted operational sales grew 5.5%. Adjusted net earnings inched 0.5% higher to $5.7 billion and adjusted EPS rose by 2% to $2.10 per diluted share.

For Johnson & Johnson, US sales inched 2% higher to $10.1 billion. However, international sales slipped about 2% to $9.9 billion.

Consumer sales slowed by 2% to $3.3 billion and Medical Devices sales slumped 5% to $6.5 billion, while Pharmaceuticals top-line improved 4% to $10.2 billion.

Johnson & Johnson said in a statement that “the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort.”

JNJ now expects adjusted FY2019 operational sales to rise 2.5-3.5%. Operational sales is expected to be $82.0-82.8 billion for the year.

“Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth,” said CEO Alex Gorsky

“At the same time, we remain focused on investing in innovative technologies and platforms that will make a meaningful difference in the lives of patients around the world. I am proud of our global colleagues’ collective efforts to deliver on our long-term goals and our ability to create value for all of our stakeholders,” the JNJ chief added as Johnson & Johnson posted its first-quarter results.

 

 

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Lennar (LEN) believes that despite near-term challenges, the long-term prospects for housing remain strong

Shares of Lennar Corporation (NYSE: LEN) were down 3% on Monday. The stock has dropped 36% year-to-date and 25% over the past 12 months. The homebuilder delivered mixed results for

KB Home (KBH): What did and did not work for the homebuilder in the third quarter

Shares of KB Home (NYSE: KBH) were up slightly on Friday. The stock has dropped 40% year-to-date and 35% over the past 12 months. The company delivered mixed results for

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top